Skip to main content
. 2018 Jun 19;9:1387. doi: 10.3389/fimmu.2018.01387

Figure 1.

Figure 1

Non-myeloablative AHSCT preserved pancreatic β cell function in patients newly diagnosed with T1D. (A) Line graph showing 2 h peak-stimulated C-peptide levels after a mixed meal tolerance test following AHSCT, at 12 and 24 months of follow-up. (B) Correlation between the number of HSPCs injected during AHSCT and 2 h peak-stimulated C-peptide levels evaluated at 6 months of follow-up. (C,D) Correlation between the number of hematopoietic stem cells (HSPCs) injected during AHSCT and EIR evaluated at 8 months (C) and 12 months (D) of follow-up. All data are expressed as mean ± SEM. All parameters examined were statistically significantly different when comparing baseline values vs. those at 6, 8, and 12 months. *P < 0.05, **P < 0.001. Abbreviations: AHSCT, autologous hematopoietic stem and progenitor cell transplantation; UI, units of insulin; EIR, exogenous insulin requirement units; HSPCs, hematopoietic stem and progenitor cells; T1D, type 1 diabetes.